Agilent Technologies selected as primary provider of gas-phase testing instruments for 2010 World Cup

Agilent Technologies Inc. (NYSE: A) today announced it has been selected by the South African Doping Control Laboratory as the primary provider of gas-phase testing instruments for the 2010 World Cup. The South African Doping Control Laboratory is certified by the World Anti-Doping Agency and will be responsible for all doping testing during the competition.

“This instrument is significantly increasing the sensitivity and specificity of detection.”

The South African Doping Control Laboratory is equipped with state-of-the-art Agilent gas chromatography (GC) and mass spectrometry (MS) instruments to confirm the chemical identity of suspected banned substances found in testing samples. Agilent is providing five GC/MSD systems and an Agilent 7000 Series Triple Quadrupole GC/MS system. Agilent technicians will provide technical support throughout the event.

"The use of the 7000 Series Triple Quadrupole GC/MS system from Agilent has raised the standard of doping testing to a higher level," said Dr. Pieter J. van der Merwe, Director, South African Doping Control Laboratory. "This instrument is significantly increasing the sensitivity and specificity of detection."

"Agilent is proud of our leadership role in anti-doping testing instruments, which dates back to the 1970s," said Mike McMullen, president of Agilent's Chemical Analysis Group. "We are honored that the South African Doping Control Laboratory selected Agilent to help ensure a level playing field and fair competition at the 2010 World Cup."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study reveals underuse of antivirals for children hospitalized with influenza